Fadi Braiteh, MD earned his medical degree in 1998 from Saint Joseph University in Beirut, Lebanon. In 2003, he completed his internal medicine internship and residency at the Hospital of Saint Raphael, Yale School of Medicine in New Haven, Connecticut. From 2003-2009, Dr. Braiteh completed three fellowships – medical oncology, phase I drug development and palliative care and symptom management – at the University of Texas M.D. Anderson Cancer Center in Houston, Texas, while he earned PhD credits for a program in molecular biology and human investigation.
Dr. Braiteh is a medical oncologist and Director of the Translational Oncology Program (TOP)-Phase I and GI Malignancies Program for Comprehensive Cancer Centers of Nevada. He is board certified in medical oncology and palliative medicine and specializes in the area of gastrointestinal and thoracic oncology as well as the development of novel anti-cancer agents through research.
Prior to joining CCCN in 2010, Dr. Braiteh worked as a medical oncologist and Director of the Phase I Program and Drug Development Center at the Cancer and Hematology Centers of Western Michigan in Grand Rapids, Michigan. During this time, he was a Clinical Assistant Professor of Medicine at the School of Human Medicine at Michigan State University, and scientific investigator for Program of Translational Medicine and Phase I clinical trials at Van Andel Research Institute in Grand Rapids, Michigan.
Dr. Braiteh has published more than 80 peer-reviewed articles, abstracts and book chapters in various publications including Nature, Lancet, Journal of Clinical Oncology (JCO) and The Oncologist. He recently published an article in Nature on cancer immunotherapy for MPDL3280A (Anti-PDL1) Phase I clinical data, including PDL1 biomarker data on tumor-infiltrating immune cells. Dr. Braiteh frequently lectures about clinical research, cancer and palliative medicine to his peers. He also serves as principal investigator or co-principal investigator for more than 200 clinical research trials. Dr. Braiteh has been featured in The New York Times in relation to his work with gene mutations.
Dr. Braiteh is the recipient of numerous awards including 2014 Healthcare Headliner in Medical Research from Vegas, Inc., The 1% Top Researcher Club by US Oncology Research Network, 2014 America’s Top Oncologists by Castle-Connolly and US News & World Report, the Everyday Heroes Award from the American Red Cross, 2014 On-time Physician Award and Patients Top Choice Award from Vitals.com and 2014 Medical Marvels by Nevada Business Magazine. He also received the 2009 Susan G. Komen Scholar-In-Training award for the AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, the 2007 Jesse Jones Fellowship in Cancer Education Award and the recipient of the 2006 and 2005 ASCO Foundation Merit Award.
Hospice and Palliative Medicine
Certified Physician Investigator, Academy of Pharmaceutical Physicians and Investigators (APPI)
MEMBERSHIPS IN PROFESSIONAL ASSOCIATIONS
American Society of Clinical Oncology
American Association for Cancer Research
Academy of Pharmaceutical Physicians and Investigators
American Association for the Advancement of Science
American Medical Association
Clark County Medical Society
National Cancer Institute
Braiteh F. Tsimberidou A., Kurzrock R. “Ultimate fate of oncology Dugs approved by the Food and Drug Administration without a randomized trial.” Journal of Clinical Oncology 2009 Dec 20;27(36):6243-50. Read more.
Braiteh F., Correa A., Hofstetter WL, Lee JH, Rice DC, Vaporciyan AA, Bhutani MS, Ross WA, Komaki R., Dekovich A., Swisher SG, Ajani JA. “Association of Age and Survival in Patients with Gastroesophageal Cancer Undergoing Surgery With or Without Preoperative Therapy.” Cancer 2009 Oct 1;115(19):4450-8. Read more.
Braiteh F., Kurzrock R. “What was ahead of such a Head Injury?” Gastroenterology 2009 Jun;136(7):e3-6. Read more.
Braiteh F. Parikh A., McLaughlin. R. “A Case of Chikungunya Fever Leading to the Diagnosis of Angioimmunoblastic T-Cell Lymphoma. Acta Oncol.” 2009;48(4):624-8. Read more.
Braiteh F., Soriano A., Garcia-Manero G., Hong D., Johnson M.M. , De Padua Silva L., Yang H, Alexander S., Wolff J., Kurzrock R. “Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers.” Clinical Cancer Research 2008 Oct 1;14(19):6296-6301. Read more.
Braiteh F., Hymes S., Giralt S., Jones R., “Psoriasis remission after autologous peripheral blood stem cell transplantation for multiple myeloma.” J Clinical Oncology 2008 Sep 20;26(27):4511-3. Read more.
Braiteh F., Kurzrock R. and Johnson F. “Trichomegaly of the Eyelashes after Treatment with the Epidermal Growth Factor Receptor Inhibitor Erlotinib for Lung Cancer with EGFR Mutation J Clinical Oncology.” 2008 Jul 20;26(20):3460-2. Read more.
Fadul N, Elsayem A, Palmer L, Braiteh F., Bruera E. “Predictors of Access to Palliative Care Services (APCS) Among Patients Who Died at a Comprehensive Cancer Center.” J Palliat Med. 2007 Oct;10(5):1146-52. Read more.
Braiteh F., Elosta B, Palmer L, Reddy S, Bruera E. “Patients’ characteristics and outcomes of palliative care inpatient consults at a comprehensive cancer center.” J Palliat Med. 2007 Aug;10(4):948-55. Read more.
Braiteh F., Cohen P, Kurzrock R. “CAT scan reveals ‘Bat sign.’” Lancet 2007 Jan 20; 369(9557): 217
Braiteh F., Kurzrock R. “Langerhans Cell Histiocytosis of the Thyroid.” Journal of Clinical Oncology. 2006 Jan 20;24(3):522-3. Read more.
Braiteh F., Boxrud C, Esmaeli B, Kurzrock R. “Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha Blood.” 2005 Nov 1;106(9):2992-4. Read more.